TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38459552

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA-IM)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant
Number of subjects: 398
Study: 38459579

Group type: EXPERIMENTAL
Intervention: BAI + SFAS
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: RT + SFAS
Number of subjects: 525

Group type: COMPARATOR
Intervention: Education Control
Number of subjects: 525
Study: 38459584

Group type: EXPERIMENTAL
Intervention: Deep learning-based MRI-only workflow with synthetic CT (sCT) derived from MRI DIXON-sequence
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard therapy and imaging including both CT and MRI
Number of subjects: 54
Study: 38459585

Group type: EXPERIMENTAL
Intervention: Asfotase alfa for ≥ 6 months
Number of subjects: 190
Study: 38459598

Group type: EXPERIMENTAL
Intervention: HER2 expression detection
Number of subjects: 30
Study: 38459686

Group type: EXPERIMENTAL
Intervention: Knee flexor maximal isometric strength in the injured limb of individuals with CAI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Submaximal isometric strength of knee extensor muscles
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Submaximal isometric contractions at 20%, 50%, and 80% of maximal voluntary isometric contraction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Knee extensor and flexor muscle activation
Number of subjects: 30
Study: 38459869

Group type: EXPERIMENTAL
Intervention: Tegoprazan (TPZ), amoxicillin, clarithromycin, and bismuth (300 mg twice daily)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Tegoprazan (TPZ), amoxicillin, and clarithromycin (without bismuth)
Number of subjects: 306
Study: 38460070

Group type: EXPERIMENTAL
Intervention: Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 genes
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Use of statins
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Use of nitrofurantoin
Number of subjects: 467
Study: 38460082

Group type: EXPERIMENTAL
Intervention: Ensitrelvir 375 mg single dose
Number of subjects: 0
Study: 38460092

Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone treatment (GAHT) in transgender women (TW) after sex hormone inhibition and estradiol treatment.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone treatment (GAHT) in transgender men (TM) after estrogen suppression and testosterone treatment.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall effects of GAHT on adipose tissue function in both TW and TM.
Number of subjects: 32
Study: 38460107

Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM)
Number of subjects: 90
Study: 38460161

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 600

Group type: COMPARATOR
Intervention: Uncoated balloon
Number of subjects: 600
Study: 38460193

Group type: EXPERIMENTAL
Intervention: 15% trichloroacetic acid + 3% glycolic acid chemical peel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated hand)
Number of subjects: 20
Study: 38460525

Group type: EXPERIMENTAL
Intervention: Bivalent vaccine (NVX-CoV2373 + NVX-CoV2540)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Prototype vaccine (NVX-CoV2373)
Number of subjects: 766
Study: 38460548

Group type: EXPERIMENTAL
Intervention: riociguat
Number of subjects: 121

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121
Study: 38460754

Group type: EXPERIMENTAL
Intervention: Electronic nudges delivered via the Danish governmental electronic letter system
Number of subjects: 1182254

Group type: COMPARATOR
Intervention: Usual care (no electronic letter)
Number of subjects: 1182254
Study: 38460823

Group type: EXPERIMENTAL
Intervention: Pentaerythrityl tetranitrate
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 38460974

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) delivered by an experienced physiotherapist, with four cycles at a range of prescriptions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal endoscopy used to visualize the larynx during MI-E.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline assessments of spirometry, peak cough flow, and sniff nasal inspiratory pressure.
Number of subjects: 0
Study: 38461094

Group type: EXPERIMENTAL
Intervention: 150-mg daily aspirin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 38461275

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention (CTSP) + Services as Usual (SAU) (N=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Services as Usual (SAU) alone (N=150)
Number of subjects: 300
Study: 38461313

Group type: EXPERIMENTAL
Intervention: 100 ml natural aronia juice (verum, V) twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polyphenol-free placebo (P)
Number of subjects: 40
Study: 38461323

Group type: EXPERIMENTAL
Intervention: neoadjuvant pertuzumab with trastuzumab and docetaxel
Number of subjects: 329

Group type: COMPARATOR
Intervention: neoadjuvant placebo with trastuzumab and docetaxel
Number of subjects: 329
Study: 38461348

Group type: EXPERIMENTAL
Intervention: Run, Jump & Fun intervention (4×30 min/week of moderate-to-vigorous physical activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Move & Learn intervention (4×30 min/week focusing on embodied learning in math and Danish lessons)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (normal teaching practices)
Number of subjects: 0
Study: 38461480

Group type: EXPERIMENTAL
Intervention: Positive PCR tests at follow-up (3, 6, and 9 months)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Positive IgG tests at baseline and follow-up (3, 6, and 9 months)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Retention of positive IgG
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Vaccination status
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up of IgG seroconversion
Number of subjects: 1008
Study: 38461657

Group type: EXPERIMENTAL
Intervention: Accelerated initiation of renal-replacement therapy (RRT)
Number of subjects: 2141830

Group type: COMPARATOR
Intervention: Standard initiation of renal-replacement therapy (RRT)
Number of subjects: 2141830
Study: 38461731

Group type: EXPERIMENTAL
Intervention: Domperidone add-on 10-mg three times daily for 16 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: No add-on treatment (control)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 17
Study: 38461841

Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg every 12 weeks (8q12)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg every 16 weeks (8q16)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Aflibercept 2 mg every 8 weeks (2q8)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Aflibercept 8 mg every 12 weeks (8q12) vs 2q8
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Aflibercept 8 mg every 16 weeks (8q16) vs 2q8
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1011
Study: 38461843

Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg every 12 weeks (8q12)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg every 16 weeks (8q16)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Aflibercept 2 mg every 8 weeks (2q8)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 660
Study: 38461957

Group type: EXPERIMENTAL
Intervention: TTA-121 6U/day for 4 weeks
Number of subjects: 207

Group type: COMPARATOR
Intervention: Syntocinon 48U/day for 4 weeks
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 38462160

Group type: EXPERIMENTAL
Intervention: Hemodynamic congestion endotype (n=75)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Volume overload congestion endotype (n=50)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Systemic congestion endotype (n=20)
Number of subjects: 145
Study: 38462218

Group type: EXPERIMENTAL
Intervention: Synbiotic formula (GOS/Limosilactobacillus fermentum CECT 5716)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 460
Study: 38462256

Group type: EXPERIMENTAL
Intervention: Tafoxiparin (60 mg daily as 0.4 mL subcutaneous injections until labor onset, maximum 28 days)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Tafoxiparin (initial bolus of 7, 21, or 35 mg followed by continuous infusion at 5, 15, or 25 mg/hour until delivery; maximum duration 36 hours)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 38462265

Group type: EXPERIMENTAL
Intervention: OdonAssist inflatable device
Number of subjects: 104
Study: 38462389

Group type: EXPERIMENTAL
Intervention: CTCA guided selective ICA
Number of subjects: 343

Group type: COMPARATOR
Intervention: ICA alone
Number of subjects: 343
Study: 38462426

Group type: EXPERIMENTAL
Intervention: Foam tape application (2 x 2 inch piece of 3 M microfoam adhesive applied to the medial aspect of the upper arm for 48 hours)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Foam tape application
Number of subjects: 40
Study: 38462613

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (IDI)
Number of subjects: 15
Study: 38462625

Group type: EXPERIMENTAL
Intervention: Atogepant
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 1550
Study: 38462673

Group type: COMPARATOR
Intervention: 600 mg rifampicin daily (flat dose)
Number of subjects: 680
Study: 38462751

Group type: EXPERIMENTAL
Intervention: Short regimen containing high-dose moxifloxacin and clofazimine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Long regimen
Number of subjects: 200
Study: 38462760

Group type: EXPERIMENTAL
Intervention: PrEP use by partner(s)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Inconsistent condom use (ICU)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: STI incidence
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Age below 35 years, not being in a stable relationship, higher number of sexual partners
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Treatment as prevention (TasP)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 609
Study: 38462764

Group type: EXPERIMENTAL
Intervention: Eltrombopag, daily fixed-dose for 6 months
Number of subjects: 15
Study: 38462919

Group type: EXPERIMENTAL
Intervention: ATI-free diet
Number of subjects: 45
Study: 38462987

Group type: EXPERIMENTAL
Intervention: T-TEER (tricuspid transcatheter edge-to-edge repair)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: T-TEER
Number of subjects: 20
Study: 38463163

Group type: EXPERIMENTAL
Intervention: Mixed RV1-RV5 vaccine schedules
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Standard RV1 and RV5 schedules
Number of subjects: 1498
Study: 38463415

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) group
Number of subjects: 168
Study: 38463464

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy (performed within 72 hours after randomization)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed cholecystectomy (performed 30±5 days after randomization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 0
Study: 38463541

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) + External Beam Radiation Therapy (EBRT, median dose: 50 Gy)
Number of subjects: 50
Study: 38463677

Group type: EXPERIMENTAL
Intervention: Complex percutaneous coronary intervention (C-PCI)
Number of subjects: 11714

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR)
Number of subjects: 11714
Study: 38463680

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR measurement
Number of subjects: 2965

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR ≤0.80
Number of subjects: 2965

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR
Number of subjects: 2965
Study: 38463683

Group type: EXPERIMENTAL
Intervention: QFR-guided PCI
Number of subjects: 3825

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 3825
Study: 38464052

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study: 38464207

Group type: EXPERIMENTAL
Intervention: Intraventricular radioimmunotherapy (RIT) with 925-1850 MBq (25-50 mCi) of 131I-omburtamab
Number of subjects: 4
Study: 38464979

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38465503

Group type: EXPERIMENTAL
Intervention: Mental health intervention (specific details not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not available)
Number of subjects: 0
Study: 38465515

Group type: EXPERIMENTAL
Intervention: Apraglutide 5 mg administered subcutaneously
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy volunteers with normal renal function
Number of subjects: 2
Study: 38465592

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 4393

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 4393

Group type: EXPERIMENTAL
Intervention: Diabetes status
Number of subjects: 4393
Study: 38465623

Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt
Number of subjects: 20995

Group type: COMPARATOR
Intervention: Regular salt
Number of subjects: 20995
Study: 38465885

Group type: EXPERIMENTAL
Intervention: Foslevodopa/foscarbidopa
Number of subjects: 0
Study: 38466118

Group type: EXPERIMENTAL
Intervention: Lung microbiota characteristics in patients with low respiratory system compliance (Crs) and low ventilatory ratio (VR) characterized by Proteobacteria dominance.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lung microbiota characteristics
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lung microbiota diversity
Number of subjects: 70
Study: 38466203

Group type: EXPERIMENTAL
Intervention: Sensorimotor training (6 weeks, 3 days/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (awareness sessions about diabetes and foot care for 30 mins, every 2 weeks)
Number of subjects: 40
Study: 38466266

Group type: EXPERIMENTAL
Intervention: Monthly intervention (9 monthly video lessons and 1 week of self-monitoring per month)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Refresher intervention (an introductory session and two 4-week periods of lessons and self-monitoring at 7 and 10 months)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control intervention (monthly online newsletters)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Initial 3-month intervention (Rx Weight Loss program)
Number of subjects: 540
Study: 38466274

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (n=1541)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Aspirin alone (n=1459)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3000
Study: 38466302

Group type: EXPERIMENTAL
Intervention: CDS system with tailored, evidence-based recommendations
Number of subjects: 2026

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: CDS system
Number of subjects: 2026
Study: 38466872

Group type: EXPERIMENTAL
Intervention: VR neuroscience-based therapy (VRNT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (waitlist control)
Number of subjects: 31
Study: 38466972

Group type: EXPERIMENTAL
Intervention: Oral CBD therapy (2.5 mg per kg per day for 16 days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 38466984

Group type: EXPERIMENTAL
Intervention: Prolonged nightly fasting for 4 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prolonged nightly fasting
Number of subjects: 6
Study: 38467003

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation (1000 mg of calcium carbonate with 400 IU of vitamin D)
Number of subjects: 36282

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation
Number of subjects: 36282
Study: 38467031

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of donor B cells (0.5 × 10^6 to 4.0 × 10^6 B cells per kg body weight)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of donor B cells
Number of subjects: 15
Study: 38467131

Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy (400 mg oral once daily after a 5-week ramp-up)
Number of subjects: 258
Study: 38467273

Group type: EXPERIMENTAL
Intervention: Patient Voices Video
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Stepped Reminders
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Both video and reminders
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes via survey
Number of subjects: 1606
Study: 38467379

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 40
Study: 38467383

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (n=19)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo treatment (n=23)
Number of subjects: 42
Study: 38467604

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m2), and cisplatin (dosage not specified)
Number of subjects: 0
Study: 38467639

Group type: EXPERIMENTAL
Intervention: Bavituximab plus pembrolizumab
Number of subjects: 28
Study: 38467646

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 1551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1551
Study: 38467716

Group type: EXPERIMENTAL
Intervention: Cochleural Alternating Acoustic Beam Therapy (CAABT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional Sound Therapy (TST)
Number of subjects: 60
Study: 38467760

Group type: EXPERIMENTAL
Intervention: NT-proBNP ratio
Number of subjects: 2917

Group type: COMPARATOR
Intervention: NT-proBNP, hsCRP, and neutrophil-to-lymphocyte ratio
Number of subjects: 2917
Study: 38467864

Group type: EXPERIMENTAL
Intervention: Canon CR2 AF AF camera
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Topcon TRC-NW400
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Optomed Aurora
Number of subjects: 900
Study: 38467912

Group type: EXPERIMENTAL
Intervention: Upadacitinib (15 mg once daily)
Number of subjects: 392
Study: 38467918

Group type: EXPERIMENTAL
Intervention: CareAvenue (digital intervention with eight videos addressing unmet social needs)
Number of subjects: 600
Study: 38467945

Group type: COMPARATOR
Intervention: Immediate implant placement (IIP) without grafting
Number of subjects: 39

Group type: COMPARATOR
Intervention: Immediate implant placement (IIP) with autogenous tooth bone graft (ATBG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Simvastatin (SMV) gel mixed with ATBG around IIP
Number of subjects: 39
Study: 38468231

Group type: EXPERIMENTAL
Intervention: Low plasma levels of NRP-1
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low plasma levels of PlGF
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low plasma levels of both NRP-1 and PlGF
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: High baseline NRP-1 level
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: High baseline VEGF receptor-2 level
Number of subjects: 65
Study: 38468241

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 38468259

Group type: EXPERIMENTAL
Intervention: 1 µM quercetin for three days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2000 mg/day quercetin for 6 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 38468266

Group type: EXPERIMENTAL
Intervention: Core implementation strategies (IS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Core+ implementation strategies (IS)
Number of subjects: 12
Study: 38468293

Group type: EXPERIMENTAL
Intervention: Exposure therapy (EXP)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 380
Study: 38468320

Group type: EXPERIMENTAL
Intervention: Novel 4-month treatment regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 38468321

Group type: EXPERIMENTAL
Intervention: Early assessment Team (EaT)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 588
Study: 38468338

Group type: EXPERIMENTAL
Intervention: High-frequency plasma donors (HFPDs) donating 650 mL of plasma 3 times every 2 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Regular-frequency plasma donors (RFPDs) donating 650 mL of plasma 1 time every 2 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Whole blood donors (control group)
Number of subjects: 120
Study: 38468418

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia (CBT-I)
Number of subjects: 150
Study: 38468440

Group type: COMPARATOR
Intervention: >0% weight gain
Number of subjects: 1030

Group type: COMPARATOR
Intervention: >2.5% weight gain
Number of subjects: 1030

Group type: COMPARATOR
Intervention: >5.0% weight gain
Number of subjects: 1030
Study: 38468620

Group type: EXPERIMENTAL
Intervention: Tertile 3 (≥ 7.51 h) sleep duration
Number of subjects: 91

Group type: COMPARATOR
Intervention: Tertile 1 (≤ 6.5 h) sleep duration
Number of subjects: 91

Group type: COMPARATOR
Intervention: Tertile 2 (6.51-7.50 h) sleep duration
Number of subjects: 91
Study: 38469035

Group type: EXPERIMENTAL
Intervention: Diabetic minority women (DMW)
Number of subjects: 1437

Group type: COMPARATOR
Intervention: Other diabetic patients
Number of subjects: 1437
Study: 38469548

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole
Number of subjects: 12
Study: 38469583

Group type: EXPERIMENTAL
Intervention: Standard care with digital patient support (SC + DPS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 100
Study: 38469654

Group type: EXPERIMENTAL
Intervention: Women with significant primary MR
Number of subjects: 111